Fig. 1From: Real-world effectiveness, satisfaction, and optimization of ubrogepant for the acute treatment of migraine in combination with onabotulinumtoxinA: results from the COURAGE StudyStudy design. MIDAS, Migraine Disability Assessment; mTOQ-4, Migraine Treatment Optimization Questionnaire; PHQ-4, Patient Health Questionnaire-4Back to article page